SB 493 - Currently, the prohibition on the prescription or administration of cross-sex hormones or puberty-blocking drugs for the purpose of a gender transition for persons under 18 years of age expires on August 28, 2027. This act removes that expiration date.

This act is identical to a provision in HCS#2/SS#2/SCS/SB 10 (2025), SB 26 (2025), SB 249 (2025), SB 1185 (2024), SB 726 (2024), and SB 776 (2024), substantially similar to SB 75 (2025), and similar to provisions in HCS/HBs 1520, 1519, 2355, and 2357 (2024).

SARAH HASKINS

Statutes affected:
Introduced (1668S.01): 191.1720